Publication | Closed Access
STIMULATORY EFFECT OF THE DOPA-DECARBOXYLASE INHIBITOR Ro 4-4602 ON PROLACTIN RELEASE; INHIBITION BY L-DOPA, METERGOLINE, METHYSERGIDE AND 2-Br-α-ERGOCRYPTINE
21
Citations
0
References
1977
Year
Stimulatory EffectPsychotropic MedicationPsychopharmacologyPrl ReleasePharmacotherapyExperimental PharmacologyRo 4-4602Reproductive EndocrinologyMolecular PharmacologyInhibition By L-dopaInhibitory ActivityMethysergide AndHealth SciencesBiochemistryPrl SecretionBehavioural PharmacologyBehavioral PharmacologyMechanism Of ActionNeuropharmacologyPharmacologyClinical DisordersPhysiologyClinical PharmacologyMedicineDrug Discovery
ABSTRACT In order to evaluate the role of serotonin (5-HT) in the effect of L-dopa on prolactin (PRL) release, normal subjects received L-dopa alone or L-dopa plus a dopa-decarboxylase inhibitor (Ro 4-4602) in basal conditions and following the repeated administration of metergoline, a specific anti-5-HT agent. The inhibiting effect of L-dopa on PRL levels was enhanced by metergoline. On the contrary, L-dopa plus Ro 4-4602 induced a sharp increase in serum PRL levels. This effect was completely abolished by metergoline, which also significantly reduced fasting PRL levels in all the subjects studied. Ro 4-4602 alone induced a significant increase in serum PRL levels, similar to that commonly observed with chlorpromazine and TRH. The effect was similar in males and in females and was reproducible in experiments performed on different days. The effect of Ro 4-4602 was completely abolished by 2-Br-α-ergocryptine and metergoline, and, to a lesser degree, was reduced by methysergide. These results suggest that Ro 4-4602 is a reliable stimulus to PRL release and show that any stimulus to PRL secretion may be blocked by both dopa-minergic and anti-serotonin agents.